Bharat Biotech expects peer review of Covaxin's Phase 3 trial data in Q4 2021

Raches Ella, project lead COVID-19 Vaccines at Bharat Biotech said that there were nine publications on Covaxin so far and the efficacy paper on Phase-3 trials would be the tenth one

Press Trust of India June 09, 2021 21:06:47 IST
Bharat Biotech expects peer review of Covaxin's Phase 3 trial data in Q4 2021

An illustration of COVAXIN, the vaccine candidate for COVID-19 developed by Bharath Biotech. Image: Bharath Biotech

Hyderabad: Bharat Biotech, which is yet to publish the data of its COVID-19 vaccine Covaxin phase-3, expects a peer review of the jab in two to four months after it was given to scientific journals, Raches Ella Project Lead COVID-19 Vaccines at Bharat Biotech said on Wednesday.

In a series of tweets, Ella said there were nine publications on Covaxin so far and the efficacy paper of phase-3 trials would be the tenth one.

"To remain unbiased, Bharat/ICMR cannot access any data. Our service provider IQVIA has started the final statistical analysis. After submitting efficacy and 2 months of safety to CDSCO (July), it is expected to instantly reach a pre-print server. Peer review takes 2-4 months," he tweeted.

According to his tweet, as many as 25,800 participants took part in phase-3 trials and there were 30 separate forms pertaining to each volunteer amounting to individual data points of 70.4 lakh.

"The last participant (participant #25,800) received the second dose in mid-March, add two months (based on CDSCO/FDA requirements for 2-months post-dose-2 safety follow-up), and we are in mid-May with sufficient data for quality checks and analysis, he said in another tweet.

Meanwhile, Suchitra Ella, Joint Managing Director of Bharat Biotech, in a tweet, said Covaxin has reached private hospitals in as many as 28 cities.

Updated Date:

also read

India logs 3,207 new COVID-19 cases, 29 deaths in last 24 hours; positivity rate at 0.95%
India

India logs 3,207 new COVID-19 cases, 29 deaths in last 24 hours; positivity rate at 0.95%

India currently has 20,403 active cases of COVID-19. There has been a decrease of 232 cases in the active COVID-19 caseload in a span of 24 hours. The active cases comprise 0.05 per cent of the total coronavirus cases in the country

COVID-19: Centre to review vaccination program with States, UTs on Friday
India

COVID-19: Centre to review vaccination program with States, UTs on Friday

India's COVID-19 vaccination coverage exceeded 191.79 crores till 7 am today, as per the data shared by the health ministry

Explained: What North Korea’s COVID-19 outbreak admission could mean?
World

Explained: What North Korea’s COVID-19 outbreak admission could mean?

North Korean state media reports said on Friday a ‘fever’ has been spreading ‘explosively’ since late April, leaving six dead, 350,000 sickened and 187,800 quarantined. The surprise admission has left outsiders wondering how bad things are in the hermit nation